Hydroxypropyl Cellulose Lf

Hydroxypropyl Cellulose LF, a polymer-based substance, is currently being studied in clinical trials as a dispersible tablet for potential use in treating childhood asthma. This article explores the ongoing research and its implications for children aged 1-5 years who are hospitalized due to asthma-like symptoms.

Table of Contents

What is HYDROXYPROPYL CELLULOSE LF?

HYDROXYPROPYL CELLULOSE LF is a pharmaceutical ingredient that belongs to a class of substances known as polymers[1]. The “LF” in its name stands for “low-functionality,” which refers to specific properties of this particular form of hydroxypropyl cellulose. This substance is used in the formulation of various medications and plays a crucial role in how these medications are delivered in the body.

Uses and Applications

While the specific uses of HYDROXYPROPYL CELLULOSE LF are not directly mentioned in the provided clinical trial data, this substance is commonly used in the pharmaceutical industry for several purposes:

  • Tablet Formulation: It’s often used as a binder in tablet manufacturing, helping to hold the ingredients together.
  • Controlled Release: HYDROXYPROPYL CELLULOSE LF can be used to create controlled-release formulations, which help medications to be released slowly over time in the body.
  • Film Coating: It can be used to coat tablets, providing protection and potentially masking unpleasant tastes.
  • Thickening Agent: In liquid medications, it may serve as a thickening agent to improve consistency.

It’s important to note that HYDROXYPROPYL CELLULOSE LF itself is not an active drug, but rather an excipient – a substance that helps deliver the active ingredient in a medication[1].

How is it Administered?

According to the clinical trial information, HYDROXYPROPYL CELLULOSE LF is administered orally[1]. This means it’s taken by mouth, typically as part of a tablet or other oral medication formulation. The specific dosage would depend on the medication it’s used in and the condition being treated.

Formulation and Characteristics

HYDROXYPROPYL CELLULOSE LF is used in the formulation of dispersible tablets[1]. Dispersible tablets are designed to disintegrate quickly when placed in water or on the tongue, making them easier to swallow. This can be particularly beneficial for patients who have difficulty swallowing whole tablets, such as children or older adults.

Important Considerations

While HYDROXYPROPYL CELLULOSE LF is generally considered safe for use in pharmaceutical formulations, there are a few points to keep in mind:

  1. Allergies: As with any medication ingredient, some individuals may be allergic to HYDROXYPROPYL CELLULOSE LF. If you experience any signs of an allergic reaction after taking a medication, contact your healthcare provider immediately.
  2. Not an Active Ingredient: Remember that HYDROXYPROPYL CELLULOSE LF is not the active drug itself, but a component that helps in the formulation and delivery of the active ingredient.
  3. Pediatric Use: The clinical trial data indicates that this particular formulation is not specifically designed for pediatric use[1]. However, this may vary depending on the specific medication it’s used in.
  4. Consultation: Always consult with your healthcare provider or pharmacist if you have any questions about the ingredients in your medications, including excipients like HYDROXYPROPYL CELLULOSE LF.

In conclusion, HYDROXYPROPYL CELLULOSE LF is an important pharmaceutical ingredient that helps in the formulation and delivery of various medications. While it’s not an active drug itself, understanding its role can help patients better comprehend how their medications work and are designed.

Aspect Details
Drug Name Hydroxypropyl Cellulose LF
Formulation Dispersible tablet
Target Condition Childhood asthma
Age Group 1-5 years (12-71 months)
Study Design Randomized, controlled, double-blind trial
Primary Endpoint Duration of asthma-like episode from start of randomization
Key Secondary Endpoints Change in symptom score, length of hospitalization, need for additional medications
Potential Benefits Personalized treatment, improved understanding of childhood asthma

Ongoing Clinical Trials on Hydroxypropyl Cellulose Lf

  • Study on Azithromycin for Treating Hospitalized Children Aged 1-5 with Asthma Symptoms

    Recruiting

    1 1
    Investigated diseases:
    Denmark

Glossary

  • Asthma: A chronic lung condition characterized by difficulty breathing, wheezing, and coughing, often triggered by various factors such as allergens or respiratory infections.
  • Polymer: A large molecule composed of many repeated subunits, often used in pharmaceutical applications for its unique properties.
  • Dispersible tablet: A type of tablet that can be dispersed in liquid before administration, making it easier to swallow, especially for children or those with swallowing difficulties.
  • Placebo: A substance with no active medical effects, used as a control in clinical trials to compare against the effects of the drug being tested.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly assigned to different groups, typically a treatment group and a control group, to test the effectiveness of a new treatment or intervention.
  • Double-blind study: A research design where neither the participants nor the researchers directly involved know who is receiving the treatment and who is receiving the placebo.
  • Respiratory microbiome: The collection of microorganisms that naturally inhabit the respiratory tract, which can influence respiratory health and disease.
  • Immunological profile: A comprehensive assessment of an individual's immune system, including various components and functions that contribute to their overall immune response.

References

  1. http://clinicaltrials.eu/trial/study-on-azithromycin-for-treating-hospitalized-children-aged-1-5-with-asthma-symptoms/